Trial · NCT02819804
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 24
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hyperglycemia | Metabolism and nutrition disorders | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | White blood cell decreased | Investigations | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Neutrophil count decreased | Investigations | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Papulopustular rash | Infections and infestations | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Hypertension | Vascular disorders | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Alanine aminotransferase increased | Investigations | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Hypotension | Vascular disorders | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Lipase increased | Investigations | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Sepsis | Infections and infestations | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Abdominal pain | Gastrointestinal disorders | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Lymphocyte count decreased | Investigations | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | INR increased | Investigations | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Hyponatremia | Metabolism and nutrition disorders | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Alkaline phosphatase increased | Investigations | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Aspartate aminotransferase increased | Investigations | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Blood bilirubin increased | Investigations | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Fall | Injury, poisoning and procedural complications | Treatment (Dasatinib, Nivolumab) | 1 | 1 | |
| other | Anemia | Blood and lymphatic system disorders | Treatment (Dasatinib, Nivolumab) | 1 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02819804/events